Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140024 | PMC |
Publication Analysis
Top Keywords
Similar Publications
The importance of validation and kudos to our NSH members.
J Histotechnol
December 2020
Editor in Chief, Journal of Histotechnology for NSH , Bozeman, MT,
Kudos to Editor John Hagan, III, MD.
Mo Med
January 2017
Gastroenterology, St. Louis, MSMA member since 1997.
JOSPT Provides Kudos Service to Authors.
J Orthop Sports Phys Ther
July 2015
Editor-in-Chief, JOSPT.
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.
Oncologist
April 2012
Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Background: BRCA1 and BRCA2 germline mutations are associated with an elevated risk for pancreas adenocarcinoma (PAC). Other BRCA-associated cancers have been shown to have greater sensitivity to platinum and poly(ADP-ribose) polymerase (PARP) inhibitors with better clinical outcomes than in sporadic cases; however, outcomes in BRCA-associated PAC have not been reported.
Methods: Patients with a known BRCA1 or BRCA2 mutation and a diagnosis of PAC were identified from the Gastrointestinal Oncology Service, Familial Pancreas Cancer Registry, and Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!